Headlines about Bruker (NASDAQ:BRKR) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a news impact score of 0.15 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.7088869735254 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern’s rankings:
- Bruker Co. (BRKR) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Bruker Co. (BRKR) Expected to Announce Quarterly Sales of $506.92 Million (americanbankingnews.com)
- $0.49 Earnings Per Share Expected for Bruker Co. (BRKR) This Quarter (americanbankingnews.com)
- Bruker (BRKR) Given Hold Rating at Cowen (americanbankingnews.com)
A number of equities research analysts have weighed in on the company. Cowen reiterated a “hold” rating and issued a $35.00 target price on shares of Bruker in a report on Thursday, December 21st. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a report on Thursday, December 14th. Citigroup boosted their price objective on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Wednesday, November 8th. Finally, Bank of America upgraded Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $30.58.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. Bruker’s revenue was up 10.6% compared to the same quarter last year. sell-side analysts anticipate that Bruker will post 1.19 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 22nd. Investors of record on Monday, December 4th were issued a dividend of $0.04 per share. The ex-dividend date was Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.47%. Bruker’s dividend payout ratio (DPR) is currently 17.02%.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
What are top analysts saying about Bruker? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bruker and related companies.